South Korea · Delayed Price · Currency is KRW GC Biopharma Statistics
Total Valuation
GC Biopharma has a market cap or net worth of KRW 1.63 trillion. The enterprise value is 2.74 trillion.
| Market Cap | 1.63T |
| Enterprise Value | 2.74T |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
GC Biopharma has 11.41 million shares outstanding.
| Current Share Class | 11.41M |
| Shares Outstanding | 11.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 14.37% |
| Float | 5.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 36.58 |
| PS Ratio | 0.82 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | 60.05 |
| P/OCF Ratio | 16.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.85, with an EV/FCF ratio of 100.94.
| EV / Earnings | -585.31 |
| EV / Sales | 1.37 |
| EV / EBITDA | 13.85 |
| EV / EBIT | 24.91 |
| EV / FCF | 100.94 |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.20 |
| Quick Ratio | 0.40 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 6.32 |
| Debt / FCF | 36.24 |
| Interest Coverage | 1.35 |
Financial Efficiency
Return on equity (ROE) is -2.06% and return on invested capital (ROIC) is 2.84%.
| Return on Equity (ROE) | -2.06% |
| Return on Assets (ROA) | 1.48% |
| Return on Invested Capital (ROIC) | 2.84% |
| Return on Capital Employed (ROCE) | 3.71% |
| Weighted Average Cost of Capital (WACC) | 7.18% |
| Revenue Per Employee | 975.16M |
| Profits Per Employee | -2.29M |
| Employee Count | 2,042 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.76 |
Taxes
| Income Tax | -5.65B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.00% in the last 52 weeks. The beta is 0.88, so GC Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +21.00% |
| 50-Day Moving Average | 157,150.00 |
| 200-Day Moving Average | 143,470.50 |
| Relative Strength Index (RSI) | 43.71 |
| Average Volume (20 Days) | 37,732 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Biopharma had revenue of KRW 1.99 trillion and -4.67 billion in losses. Loss per share was -410.00.
| Revenue | 1.99T |
| Gross Profit | 552.64B |
| Operating Income | 67.81B |
| Pretax Income | -35.33B |
| Net Income | -4.67B |
| EBITDA | 155.46B |
| EBIT | 67.81B |
| Loss Per Share | -410.00 |
Balance Sheet
The company has 50.80 billion in cash and 982.14 billion in debt, with a net cash position of -931.34 billion or -81,602.53 per share.
| Cash & Cash Equivalents | 50.80B |
| Total Debt | 982.14B |
| Net Cash | -931.34B |
| Net Cash Per Share | -81,602.53 |
| Equity (Book Value) | 1.39T |
| Book Value Per Share | 106,673.41 |
| Working Capital | 224.44B |
Cash Flow
In the last 12 months, operating cash flow was 99.46 billion and capital expenditures -72.36 billion, giving a free cash flow of 27.10 billion.
| Operating Cash Flow | 99.46B |
| Capital Expenditures | -72.36B |
| Depreciation & Amortization | 87.66B |
| Net Borrowing | 130.28B |
| Free Cash Flow | 27.10B |
| FCF Per Share | 2,374.52 |
Margins
Gross margin is 27.75%, with operating and profit margins of 3.41% and -0.23%.
| Gross Margin | 27.75% |
| Operating Margin | 3.41% |
| Pretax Margin | -1.77% |
| Profit Margin | -0.23% |
| EBITDA Margin | 7.81% |
| EBIT Margin | 3.41% |
| FCF Margin | 1.36% |
Dividends & Yields
This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.08%.
| Dividend Per Share | 1,500.00 |
| Dividend Yield | 1.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 1.07% |
| Earnings Yield | -0.29% |
| FCF Yield | 1.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.
| Last Split Date | Jun 7, 2013 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
GC Biopharma has an Altman Z-Score of 1.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 5 |